Bright Minds Biosciences (DRUG) Equity Average (2023 - 2026)

Bright Minds Biosciences has reported Equity Average for 4 years, with the latest figure at $182.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 188.67% year-over-year to $182.4 million; the trailing twelve-month figure through Mar 2026 stood at $182.4 million (up 188.67% YoY), and the FY2025 full-year result was $57.8 million, up 274.0% from the prior year.
• Equity Average for Q1 2026 stood at $182.4 million, up from $93.8 million in the prior quarter.
• The five-year high for Equity Average was $182.4 million in Q1 2026, with the low at $15.3 million in Q4 2023.
• Historically, Equity Average has averaged $70.8 million across 4 years, with a median of $63.5 million in 2025.
• The largest YoY upside for Equity Average was 199.37% in 2025 against a maximum downside of 109.2% in 2025.
• Bright Minds Biosciences' Equity Average stood at $15.3 million in 2023, then soared by 192.49% to $44.8 million in 2024, then surged by 109.2% to $93.8 million in 2025, then jumped by 94.42% to $182.4 million in 2026.
• The last three Equity Average figures came in at $182.4 million (Q1 2026), $93.8 million (Q4 2025), and $77.2 million (Q3 2025), per Business Quant data.